Pulmonary and antiaggregatory effects of prostacyclin after inhalation and intravenous infusion.
Prostacyclin (PGI2) was administered by inhalation (50 micrograms/min) and intravenous infusion (15 ng/kg/min) in 5 healthy male volunteers. Irrespective of the route of administration this substance was shown to have no effects on respiratory indices studied, whereas a significant inhibition of ADP-induced platelet aggregation and a fall in vascular resistance could be demonstrated. Mainly because of the latter action it is suggested that PGI2, or a stable synthetic analogue, might become a potent drug in various pathological conditions, in which hypertension of various causes is a problem.
D000328:Adult; D000336:Aerosols; D000925:Anticoagulants; D003864:Depression, Chemical; D004341:Drug Evaluation; D011464:Epoprostenol / Q000008:administration & dosage*; D005541:Forced Expiratory Volume; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008448:Maximal Expiratory Flow Rate; D010974:Platelet Aggregation / Q000187:drug effects*; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage*; D012119:Respiration / Q000187:drug effects*; D014655:Vascular Resistance / Q000187:drug effects; D014797:Vital Capacity
D000336:Aerosols; D000925:Anticoagulants; D011465:Prostaglandins, Synthetic; D011464:Epoprostenol